查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465205

依替巴肽市场：按类型、按应用分类 - 2024-2030 年全球预测

Eptifibatide Market by Type (0.75mg/ml Eptifibatide, 2mg/ml Eptifibatide), Application (Myocardial Infarction, Unstable Angina) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年埃替巴肽市场规模为38,982万美元，预计2024年将达4,1106万美元，2030年将达57,729万美元，复合年增长率为5.76%。

Eptifibatide 是一种环状七胜胜肽，源自东南部侏儒响尾蛇 (Sistrurus miliarius barbouri) 毒液中的蛋白质。依替巴肽是一种血小板凝集抑制剂，在预防血栓形成中发挥重要作用，广泛用于经经皮冠状动脉成形术（PCI）。心血管疾病盛行率的显着增加以及易患心臟病的老年人口数量的增加正在推动全球对依替巴肽的需求。经经皮治疗 (PCI) 手术的进步正在推动依替巴肽使用的创新。有利的报销政策和不断增长的医疗保健支出也对市场扩张做出了重大贡献。儘管存在成长前景，但与依替巴肽相关的显着副作用（包括出血风险）可能会阻碍市场采用。遵守严格的监管标准也是市场拓展的一大挑战。此外，药物配方和药物传输技术的不断进步也凸显了潜在发展和成长的领域。持续的研究和开发工作探索依替巴肽与其他抗血小板药物的协同组合可能会开闢新的市场渗透途径。

主要市场统计
基准年[2023] 38982万美元
预测年份 [2024] 41106万美元
预测年份 [2030] 57729万美元
复合年增长率（%） 5.76%

2mg/ml 型製剂日益成为急性期给药的首选

0.75 mg/ml 依替巴肽製剂通常在一段时间内连续输注，通常先大剂量投药，然后维持剂量。 0.75mg/ml特别适合因体重或肾功能等某些临床因素而需要较低剂量的患者。 0.75 mg/ml 配方可达到精确剂量，通常用于需要滴定或逐渐减少抗血小板作用的治疗方案。依替巴肽 2 mg/ml 製剂专为需要快速抑制血小板的高压力情况下的急性给药而设计，例如经皮冠状动脉经皮治疗 (PCI) 期间和之后立即给药。高浓度允许快速推注，然后进行维持大剂量投药，维持输注可根据临床反应和患者状况进行调整。

应用型心肌梗塞的多种应用

依替巴肽作为治疗方法的一部分给予，透过防止进一步形成血栓来降低随后发生心血管事件的风险。在心肌梗塞病例中基于需求的依替巴肽偏好源于其在经皮冠状动脉介入治疗（PCI）期间改善患者预后的功效。不稳定型心绞痛是一种由心臟血流量减少引起的胸痛，是依替巴肽的另一个重要应用领域。与心肌梗塞类似，依替巴肽的作用是防止血小板凝集，进而降低心臟病发作的风险。

区域洞察

在美洲，特别是在美国和加拿大，依替巴肽的使用受到先进的医疗基础设施和心血管疾病高盛行率的严重影响。在美国和加拿大，专利悬崖正在增加学名药的使用并影响客户的购买行为。在欧盟（EU），由于人口老化和心血管疾病的增加，依替巴肽的需求很大。欧洲国家拥有发达的医疗保健系统，降低医疗成本的努力正在影响依替巴肽的市场动态。医疗基础设施相对发达、收入水平较高的中东地区对包括依替巴肽在内的先进治疗方案的需求正在增加。有限的医疗设施和负担能力问题限制了依替巴肽在非洲市场的采用。在亚太地区，中国、日本、印度等国家由于人口众多、心血管疾病发生率不断上升，在依替巴肽市场中占有至关重要的地位。受政府改善医疗保健和促进依替巴肽等药物本地生产措施的影响，中国市场正在快速成长。日本拥有先进的医疗保健系统，仍然是专注于创新治疗解决方案的重要消费国。印度市场的特点是医疗保健意识不断增强且价格低廉，学名药正在推动亚太地区的市场成长。

FPNV定位矩阵

FPNV定位矩阵对于评估依替巴肽市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对依替巴肽市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 依替巴肽市场规模及预测是多少？

2.依替巴肽市场预测期间有哪些产品、细分市场、应用和领域值得考虑投资？

3.依替巴肽市场的技术趋势和法规结构是什么？

4.依替巴肽市场主要厂商的市场占有率是多少？

5. 进入依替巴肽市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 心血管疾病发生率上升，易患心臟病的老年人口增加
      • 经经皮冠状动脉介入治疗 (PCI) 技术的持续进步
      • 医疗费用上涨和有利的报销政策
    • 抑制因素
      • 与使用依替巴肽相关的副作用和安全风险
    • 机会
      • 药物配方和给药技术的不断进步
      • 研发活动持续追求与其他抗血小板药物的协同效应
    • 任务
      • 遵守严格的监管标准
  • 市场区隔分析
    • 类型：2mg/ml 製剂越来越适合急性给药
    • 应用：心肌梗塞的多种应用范围
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章依替巴肽市场：依类型

  • 0.75mg/ml依替巴肽
  • 2mg/ml依替巴肽

第七章依替巴肽市场：依应用分类

  • 心肌梗塞
  • 不稳定型心绞痛

第八章 美洲依替巴肽市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太依替巴肽市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲依替巴肽市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 新研究发现抗血小板治疗可改善致命性脑出血患者的预后
    • 加拿大医院因关键药物短缺而苦苦挣扎，朱诺製药公司获得依替巴肽进口核准
  • 战略分析和建议

第12章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-6D54EA0F945B

[184 Pages Report] The Eptifibatide Market size was estimated at USD 389.82 million in 2023 and expected to reach USD 411.06 million in 2024, at a CAGR 5.76% to reach USD 577.29 million by 2030.

Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Eptifibatide is a platelet aggregation inhibitor playing a significant role in preventing blood clots and is widely used during percutaneous coronary intervention (PCI) procedures. The significant rise in prevalence of cardiovascular diseases and growing elderly population, more prone to cardiac conditions, drive the necessity of the Eptifibatide worldwide. The advancements in percutaneous coronary intervention (PCI) techniques drive the innovation in the utilization of Eptifibatide. The favorable reimbursement policies and increased healthcare expenditure also significantly contribute to market expansion. Despite the growth prospects, significant side effect profiles associated with Eptifibatide, such as bleeding risks, may hinder its adoption in the market arena. The compliance with stringent regulatory standards also poses a substantial challenge for the market expansion. Moreover, continuous advancements in drug formulation and delivery techniques also spotlight potential areas for development and growth. Ongoing R&D initiatives to explore synergistic combinations of Eptifibatide with other antiplatelet agents can pave new paths for product penetration in the market space.

KEY MARKET STATISTICS
Base Year [2023] USD 389.82 million
Estimated Year [2024] USD 411.06 million
Forecast Year [2030] USD 577.29 million
CAGR (%) 5.76%

Type: Increasing preference of 2 mg/ml formulation for acute administration

The 0.75mg/ml of Eptifibatide is generally used for continuous infusion over a period, often starting with a bolus dose followed by maintenance dosing. 0.75mg/ml is particularly suited for patients that require a lower dose due to specific clinical factors such as weight or renal function. The 0.75mg/ml solution allows for precise dosing adjustments and is commonly preferred in treatment protocols that necessitate gradual escalation or reduction of the antiplatelet effect. The Eptifibatide's 2mg/ml formulation is designed for acute administration, particularly in high-stress scenarios requiring rapid platelet inhibition, such as during or immediately after percutaneous coronary interventions (PCI). The higher concentration enables quicker administration of a bolus dose, followed by a maintenance infusion that can be adjusted based on clinical response and patient condition.

Application: Diverse scope of applications in myocardial infarction

Eptifibatide is administered as part of the therapeutic regimen to prevent further clot formation, thus reducing the risk of subsequent cardiovascular events. The need-based preference for Eptifibatide in myocardial infarction cases stems from its effectiveness in enhancing patient outcomes during percutaneous coronary intervention (PCI). Unstable Angina, a type of chest pain caused by reduced blood flow to the heart, is another critical application area for Eptifibatide. Similar to MI, Eptifibatide's role is centered on preventing platelet aggregation, thus mitigating the risk of a heart attack.

Regional Insights

In the Americas, particularly the United States and Canada, the usage of Eptifibatide is significantly influenced by the advanced healthcare infrastructure and high prevalence of cardiovascular diseases. In the United States and Canada, patent cliffs have led to increased availability of generic versions, impacting customers' purchasing behaviors in the region. The European Union (EU) exhibits a high demand for Eptifibatide largely due to the aging population and the consequent rise in cardiovascular diseases. European countries have a robust healthcare system and initiatives to reduce healthcare expenditure, which influences the Eptifibatide market dynamics. Due to its relatively better healthcare infrastructure and higher income levels, the Middle East region shows a growing demand for advanced therapeutic options including Eptifibatide. Limited healthcare facilities and affordability issues constrain the African market for the adoption of eptifibatide. In the Asia Pacific region, countries such as China, Japan, and India are pivotal in the Eptifibatide market due to their large populations and increasing incidence of cardiovascular diseases. China's market is growing rapidly, influenced by government initiatives to improve healthcare and boost the local production of pharmaceuticals, including Eptifibatide. With its advanced healthcare system, Japan continues to be a significant consumer, focusing on innovative treatment solutions. India's market is characterized by growing healthcare awareness and affordability issues, with generic drugs contributing to the market growth in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Eptifibatide Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Eptifibatide Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Eptifibatide Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Amneal Pharmaceuticals LLC, Baxter International Inc., Eugia US LLC, GlaxoSmithKline PLC, Hybio Pharmaceutical Co., Ltd., Kensington Pharma, Merck & Co., Inc., Novetide Ltd., Sagent Pharmaceuticals, Slate Run Pharmaceuticals, Strides Pharma Canada Inc., and Taj Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Eptifibatide Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • 0.75mg/ml Eptifibatide
    • 2mg/ml Eptifibatide
  • Application
    • Myocardial Infarction
    • Unstable Angina
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Eptifibatide Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Eptifibatide Market?

3. What are the technology trends and regulatory frameworks in the Eptifibatide Market?

4. What is the market share of the leading vendors in the Eptifibatide Market?

5. Which modes and strategic moves are suitable for entering the Eptifibatide Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cardiovascular diseases and growing elderly population, more prone to cardiac conditions
      • 5.1.1.2. Ongoing advancements in percutaneous coronary intervention (PCI) techniques
      • 5.1.1.3. Increased healthcare expenditure and favorable reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Side effect and safety risks associated with use of Eptifibatide
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in drug formulation and delivery techniques
      • 5.1.3.2. Ongoing R&D initiatives to explore synergistic combinations with other antiplatelet agents
    • 5.1.4. Challenges
      • 5.1.4.1. Compliance with stringent regulatory standards
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing preference of 2 mg/ml formulation for acute administration
    • 5.2.2. Application: Diverse scope of applications in myocardial infarction
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Eptifibatide Market, by Type

  • 6.1. Introduction
  • 6.2. 0.75mg/ml Eptifibatide
  • 6.3. 2mg/ml Eptifibatide

7. Eptifibatide Market, by Application

  • 7.1. Introduction
  • 7.2. Myocardial Infarction
  • 7.3. Unstable Angina

8. Americas Eptifibatide Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Eptifibatide Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Eptifibatide Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Anti-platelet Therapy Could Help Improve Outcomes For Patients With a Deadly Form of Brain Bleed, New Study Reveals
    • 11.3.2. Juno Pharmaceuticals Receives Approval to Import Eptifibatide as Canadian Hospitals Continue to Grapple with Shortages of Critical Medicines
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. EPTIFIBATIDE MARKET RESEARCH PROCESS
  • FIGURE 2. EPTIFIBATIDE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EPTIFIBATIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. EPTIFIBATIDE MARKET DYNAMICS
  • FIGURE 7. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EPTIFIBATIDE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. EPTIFIBATIDE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EPTIFIBATIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EPTIFIBATIDE MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL EPTIFIBATIDE MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 0.75MG/ML EPTIFIBATIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 0.75MG/ML EPTIFIBATIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 2MG/ML EPTIFIBATIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 2MG/ML EPTIFIBATIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL EPTIFIBATIDE MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL EPTIFIBATIDE MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL EPTIFIBATIDE MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL EPTIFIBATIDE MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. AMERICAS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 20. AMERICAS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 21. AMERICAS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 22. AMERICAS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 25. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 26. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 27. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 28. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 29. BRAZIL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. BRAZIL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. BRAZIL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. BRAZIL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. CANADA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. CANADA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. CANADA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. CANADA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. MEXICO EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. MEXICO EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. MEXICO EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. MEXICO EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. CHINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. CHINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. CHINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. CHINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. INDIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. INDIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. INDIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. INDIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. INDONESIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. INDONESIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. INDONESIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. INDONESIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. JAPAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. JAPAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. JAPAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. JAPAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. TAIWAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. TAIWAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. TAIWAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. TAIWAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. THAILAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. THAILAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. THAILAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. THAILAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. VIETNAM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. VIETNAM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. VIETNAM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. VIETNAM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. DENMARK EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. DENMARK EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. DENMARK EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. DENMARK EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. EGYPT EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. EGYPT EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. EGYPT EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 114. EGYPT EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 115. FINLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. FINLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. FINLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. FINLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. FRANCE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. FRANCE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. FRANCE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. FRANCE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. GERMANY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. GERMANY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. GERMANY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. GERMANY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. ISRAEL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. ISRAEL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. ISRAEL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. ISRAEL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. ITALY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. ITALY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. ITALY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. ITALY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. NIGERIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. NIGERIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. NIGERIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. NIGERIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. NORWAY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. NORWAY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. NORWAY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. NORWAY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. POLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. POLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. POLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. POLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. QATAR EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. QATAR EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. QATAR EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. QATAR EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. RUSSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. RUSSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. RUSSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. RUSSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. SPAIN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SPAIN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SPAIN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. SPAIN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SWEDEN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SWEDEN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SWEDEN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. SWEDEN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. TURKEY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. TURKEY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. TURKEY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. TURKEY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. EPTIFIBATIDE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. EPTIFIBATIDE MARKET, FPNV POSITIONING MATRIX, 2023